<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01353703</url>
  </required_header>
  <id_info>
    <org_study_id>111157</org_study_id>
    <nct_id>NCT01353703</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccine</brief_title>
  <official_title>Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Infanrix Hexa™ Vaccine in Healthy Infants in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study evaluates the immunogenicity and safety of Infanrix hexa™ (DTPa-HBV-IPV/Hib) when
      administered as a primary vaccination course to Indian infants according to a 6-10-14 weeks
      or a 2-4-6 months schedule.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccine, in terms of number of seroprotected subjects</measure>
    <time_frame>One month after the third dose of primary vaccination, i.e. at the age of 18 weeks or 7 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity with respect to components of the study vaccine in terms of antibody titres</measure>
    <time_frame>Before the first dose of primary vaccination (Day 0) and one month after the third dose of primary vaccination, i.e. at the age of 18 weeks or 7 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of solicited local and general symptoms</measure>
    <time_frame>During the 4-day (Day 0-Day 3) follow-up period after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of unsolicited adverse events</measure>
    <time_frame>During the 31-day (Day 0-Day 30) follow-up period after each vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>From Dose 1 (Day 0) up to study end i.e. at the age of 18 weeks or 7 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">214</enrollment>
  <condition>Poliomyelitis</condition>
  <condition>Tetanus</condition>
  <condition>Acellular Pertussis</condition>
  <condition>Haemophilus Influenzae Type b</condition>
  <condition>Diphtheria</condition>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Infanrix hexa™ at 6, 10 and 14 weeks of age</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive Infanrix hexa™ at 2, 4 and 6 months of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infanrix hexa™</intervention_name>
    <description>Intramuscular, three doses</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group A</arm_group_label>
    <other_name>DTPa-HBV-IPV/Hib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All subjects must satisfy ALL the following criteria at study entry:

          -  A male or female between, and including, 6 and 10 weeks of age at the time of the
             first vaccination

          -  Documented administration of a hepatitis B vaccine dose at birth

          -  Subjects who the investigator believes that their parent(s)/legally acceptable
             representative(s) [LAR(s)] can and will comply with the requirements of the protocol

          -  Written informed consent obtained from the parent(s)/LAR(s) of the subject

          -  Healthy subjects as established by medical history and clinical examination before
             entering into the study

          -  Born after a gestation period of at least 36 weeks

        Exclusion Criteria:

        The following criteria should be checked at the time of study entry. If ANYexclusion
        criterion applies, the subject must not be included in the study:

          -  Child in care

          -  Use of any investigational or non-registered product other than the study vaccines
             within 30 days preceding the first dose, or planned use during the study period

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose

          -  Administration of a vaccine not foreseen by the study protocol, within 30 days prior
             to the first study visit, or planned administration during the study period, with the
             exception of oral human rotavirus (HRV) vaccination which is allowed at any time
             during the study

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product

          -  Evidence of previous diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and
             Haemophilus influenzae type b (Hib) vaccination or disease, with the exception of a
             birth dose of hepatitis B vaccine and oral poliovirus vaccine (OPV) as per local
             standard of care

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical examination

          -  Family history of congenital or hereditary immunodeficiency

          -  History of any reaction or hypersensitivity likely to be exacerbated by any component
             of the vaccine

          -  Major congenital defects or serious chronic illness

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period

          -  Acute disease and/or fever at the time of enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>10 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belgaun</city>
        <zip>590010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chennai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pune</city>
        <zip>411018</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2011</study_first_submitted>
  <study_first_submitted_qc>May 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2011</study_first_posted>
  <disposition_first_submitted>April 18, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 18, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 26, 2013</disposition_first_posted>
  <last_update_submitted>July 10, 2014</last_update_submitted>
  <last_update_submitted_qc>July 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infanrix hexa™</keyword>
  <keyword>Primary vaccination</keyword>
  <keyword>India</keyword>
  <keyword>combination vaccine</keyword>
  <keyword>infants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 26, 2017</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>October 23, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

